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Fee-For-Service as a Business Model
of Growing Importance:
The Academic Biobank Experience
Sandra A. McDonald,1 Kara Sommerkamp,2 Maureen Egan-Palmer,2
Karen Kharasch, 2 and Victoria Holtschlag1

Biorepositories offer tremendous scientific value to a wide variety of customer groups (academic, commercial,
industrial) in their ability to deliver a centralized, standardized service model, encompassing both biospecimen
storage and related laboratory services. Generally, the scientific expertise and economies of scale that are offered
in centralized, properly resourced research biobanks has yielded value that has been well-recognized by universities, pharmaceutical companies, and other sponsoring institutions. However, like many facets of the
economy, biobanks have been under increasing cost pressure in recent years. This has been a particular problem
in the academic arena, where direct support from grant sources (both governmental and philanthropic) typically
now is more difficult to secure, or provides reduced financial support, relative to previous years. One way to
address this challenge is to establish or enhance a well-defined fee-for-service model which is properly calibrated
to cover operational costs while still offering competitive value to users. In this model, customers are never
charged for the biospecimens themselves, but rather for the laboratory services associated with them. Good
communication practices, proper assessment of value, implementation of best practices, and a sound business
plan are all needed for this initiative to succeed. Here we summarize our experiences at Washington University
School of Medicine in the expectation they will be useful to others.

Introduction

W

ith the advent of sophisticated biomedical research technologies that can unlock the molecular
mysteries of disease, and the recognition that diseased and
normal tissue and biofluid specimens provide an invaluable
substrate for such inquiries, biorepositories have become a
key resource in recent years within many academic, commercial, governmental, and pharmaceutical institutions. The
science of biobanking has recently seen prominent recognition in the lay media,1 and arguments for its scientific merit
and resource justifications are well recognized.2
Institutional banks have grown in part from the value
(including economy-of-scale) that is provided when many
customers are served by centralized hub-and-spoke models,
instead of by small banks located within departments or
individual laboratories. The economic advantages of centralization have, in fact, been advocated on a very large scale
model.2 Centralized banks offer more efficient use of personnel, space, and resources, and allow the use of uniform
processes and policies across all biospecimen-related activities, including those required by regulatory or advisory

bodies. Also, such banks create a neutral entity for the coordinated distribution of resources while protecting patient
privacy, and they can preserve biospecimens and data beyond the tenure of individual investigators or studies. For
academic institutions, biobanks serve as a readily accessible
resource to support pilot studies and other endeavors that
can lead to grant funding, both internal and extramural.
The traditional role of biobanks, particularly academic
ones, has included support for basic and translational research. As such, they were traditionally viewed as site-based
resources for their institutions or departments, and thus
could often receive financial support from sources not requiring a fee-for-service approach. One example is support
from academic departments; often pathology departments
have administratively housed biobanks, since the specimen
accruals and subject matter/expertise are naturally relevant
to these departments’ missions. Other examples are philanthropic sources, and governmental grants such as those periodically offered through the Office of Biorepositories and
Biospecimen Research.3 The challenge to this traditional
model is that the current difficult economic climate, and the
competitive nature of the biobanking field, has reduced or

1

Department of Pathology and Immunology, and 2Siteman Cancer Center, Washington University Medical Center, St. Louis, Missouri.

421

422
curtailed many of these sources, or made them more difficult
to secure. In the meantime, the operating costs for biobanks
continue to grow, with reagents, equipment, ongoing
maintenance, and salaries all being examples of significant
‘‘overhead’’ expenses. And so, increasingly biobanks
must operate as business enterprises as well as scientific
laboratories—operating on the cutting edge of business
philosophy, collecting sufficient revenues for their valueadded services, and strategically apportioning and investing
their financial resources. Despite its importance, relatively
little has been written regarding evolving financial strategies
for biorepositories.
Like any good business, biorepositories offer a valuable
product, which they market to consumers and encourage
them to pay for. Also as with other businesses, that product
may have to compete with alternatives on the open market—
such as commercial tissue vendors, and investigators’ option to create their own bank. For a sustainable financial
model, the value of offered services—and the revenue they
generate—combined with non-fee-for-service money (i.e.,
grants or departmental support), should at least equal the
expenses involved. A good fee-for-service schedule helps
meet this standard, while also providing customers a sense
of fairness and value. A fee-for-service schedule also typically is more flexible (especially relative to grant or philanthropic support) in adapting to changes in the cost of doing
business, whether anticipated or not.
The biorepository at Washington University School of
Medicine, also known as the Tissue Procurement Core
(TPC), derives its specimens from a wide variety of clinical
trials and collection protocols. Given the long-standing
history of support from the Siteman Cancer Center at
Washington University Medical Center, the TPC focuses on
oncology. The TPC supports a wide variety of translational
and other research programs at the School of Medicine on a
request-driven basis, and in addition to storing and distributing tissues and biofluids, it also provides an array of
laboratory services. Many banking protocols interfacing
with the TPC are investigator-driven, but the TPC maintains its own Institutional Review Board (IRB)-approved
general collection protocol using discarded tissue from
surgical pathology,4 which is used to fill some requests.
Reflective of its roles, the TPC is organized into processing,
molecular, and histology divisions, with storage as a
centralized ‘‘hub’’ function. During fiscal year 2010–2011,
the repository accessioned 34,863 specimens and disbursed
11,936 specimens for 85 different internal research programs or protocols. Requests are initiated by the use of an
online request form which investigators must complete,5
and which facilitates subsequent billing. Typically, requesting investigators are expected to pay fee-for-service
charges out of their research funding, which can have a
variety of origins, some internal (i.e., institutionally sponsored) and some external.
As direct grant sources to the TPC have become less
prominent as a way of supporting it relative to ongoing
‘‘overhead’’ expenses, in response the Core has throroughly
examined each aspect of its business. Importantly, in this
model, users are never charged for the biospecimens themselves, but rather for the laboratory services associated with
them. A key approach used was to examine each laborconsuming or expense-incurring part of the overall workflow, determining whether such components
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 offered a readily apparent value to the customer, for which

that customer would be willing to pay;
 were not value-added from the customer’s point of view

(i.e., something they would not specifically be willing to
pay for) but still were necessary aspects of running the
business, or
 were not value-added from either the customer or the
business point of view and should be eliminated.
Items in the first category were considered prime candidates
for inclusion in a fee-for-service mechanism, and the methodology for that is described in this article. An important
aspect of our strategy was that some items in the second
category could potentially be moved to the first category,
and thus eligible to support the revenue stream, if persuasive
communications were able change to customers’ willingness
to pay for them. An example described further on is storage,
which through communications to the user community at
our institution, was ‘‘re-framed’’ as a value-added, specialized service that justified the imposition of charges.
We describe here the process of building a good fee-forservice approach into our financial plan. How adaptable our
approach is for other banks depends on their setting, their
areas of focus, and the nature of their customer base. Also,
nonacademic banks (e.g., pharmaceutical industry) may require a different model by virtue of having distinct objectives, and a different payer system. Nevertheless, we think
our approach is useful as a general measure to address an
increasingly challenging financial environment. For banks
already using fee-for-service, we provide recommendations
for revenue enhancement. For banks not yet using this approach, our experience may be useful in its implementation.

Discussion
There were several value-added categories of activity that
were prime candidates for inclusion in a fee-for-service
schedule (Table 1): storage, accessioning and disbursal, laboratory procedures, and pathology review. For each of these,
proper analysis and cost-accounting required us to evaluate
the relative contributions of three key cost components (Table 2): reagents/consumables, depreciation, and labor.
Reagents and consumables pertain to those items, both
chemical (e.g., xylene, Ficoll-Paque PlusTM reagent) and
material (e.g., plastic tubes, slides) which are necessary to
perform requested tasks. The quantities and costs needed for
such items should be scaled to reflect the expected overall
volume and trends of activity, after which it is fairly
straightforward to calculate cost on a per-procedure basis,
and build this amount into the quoted fee for that procedure.
The second component of the cost analysis is infrastructure, which accounts for the large capital equipment needed
to do a given procedure in a given laboratory area, and in
so doing, builds needed capital equipment into the costrecovery model. Charges for infrastructure thus vary across
different laboratory workflows; for example, costs for frozen
sections will be influenced by cryostats, whereas those for
blood processing procedures will pertain to centrifuges and
freezers. In addition, the cost of service contracts may also be
included in building the infrastructure component. The laboratory must assure compliance with applicable government
regulations (e.g., U.S. Office of Management and Budget
Circular A-21 and A-133), and therefore, laboratories must
work in partnership with their university administration.

FEE-FOR-SERVICE
Table 1.
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Value-added Categories of Activity for Inclusion in a Fee-for-Service Schedule

Item
Accessioning
and Disbursal

Laboratory
Services

Pathology
Review

Storage

Description

Examples and Comments

Taking in new specimens, and later disbursing
them to requesting investigators, are
procedures needing both time and expertise,
involving chain-of-custody measures,
computer entry, and communication practices.
Collectively, these services form TPC’s most
visible and recognized core of value in its
scientific mission, and thus they represent
items which investigators readily identify
with, and show willingness to pay for. Specific
services are itemized on the fee schedule for
customers to see and choose from.
This is an essential component of the lab, given
the focus on neoplastic disease, and the
frequent use of tissues and tissue-based
procedures in addressing investigator needs.

Accessioning and disbursal have specific charges
on the fee schedule. Mostly these are laborbased charges, with a small reagents and
consumables component for disbursal.

This charge applies only to specimens stored
under liquid nitrogen vapor, and to
investigator-sponsored protocols, and is
assessed annually based on the number of
post-processing ampules needing storage (not
necessarily the number of tubes or samples
originally submitted).

Recharge centers at Washington University (i.e., units which
charge other units at the institution for goods or services)
recover the nonsubsidized, direct costs, and such recharge
centers with less than $250,000 in annual billings do not include equipment depreciation in the billing rates.
For those laboratories that are able to include depreciation,
building an accurate infrastructure charge can be done by
dividing the purchase cost by the estimated lifespan for the
equipment (say, 10 years for a mechanical - 80C freezer),
and then dividing that figure by the number of tests expected
to be run on that equipment within the same timeframe. The
calculations’ accuracy could be further sharpened by building inflation expectations, and maintenance and repair estimates, into the figures. An obvious infrastructure cost is
long-term specimen storage, which is considered further on.

Table 2.
Item

This is handled as a specialized labor charge,
with a per-slide pathology review fee. Less
commonly, a pathology consultation fee can
apply. Such fees can be waived in certain
circumstances (see main text).
Calculating an accurate storage charge requires
the factoring of the cost of purchasing and
maintaining the freezers, and the continual
resupply of LN2 required.

However, infrastructure expenses also underlie many other
laboratory activities.
Labor, the third basic cost component, is influenced by the
institutional rate of pay (salary and benefits), the skill level
and personnel education/ training (and thus the pay rate)
needed for a given procedure, and the person-hours needed
to accomplish a task. Therefore, labor costs vary greatly
across laboratories and across various tasks within the laboratory.

Storage
The majority of TPC specimens, and the ones with the
greatest potential utility for translational research, are those
stored under liquid nitrogen (LN2) vapor (approximately

Underlying Cost Components for Each Value-added Laboratory Workflow
Description

Reagents and
Consumables

Items, both chemical and material, which are
necessary to perform requested tasks.

Infrastructure

Large capital equipment and service contracts
needed to do a given procedure in a given
laboratory area. Charges for infrastructure
vary across different laboratory workflows.
Influenced by overall rates of pay (salary and
benefits), the skill level and personnel
education/ training (and thus the pay rate)
needed for a given procedure, and the personhours needed to accomplish a task. Labor
costs vary greatly across laboratories and
across various tasks within the laboratory.

Labor

Plasma, serum, and Ficoll processing, cytospins,
tissue processing and frozen and paraffin
section preparation, and DNA and RNA
preparation and analysis. Most lab services
have the full triad of labor, infrastructure, and
reagents/consumables costs underlying them.

Examples
Xylene, Ficoll-Paque PlusTM reagent (chemical);
Eppendorf tubes and packaging equipment
(material).
Cryostats and microtomes (histology);
centrifuges (processing), freezers (storage).

Ficoll processing and laser capture microscopy
(very labor intensive); basic cell processing
(less labor intensive).
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- 120C). Currently, TPC’s storage inventory uses 21 LN2
vapor freezers, and ongoing tissue procurements and accessions require that a new LN2 freezer be purchased about
every 5–6 months. Associated expenses are high: a typical
30,000-vial-capacity LN2 vapor freezer costs approximately
$30,000–$35,000 new, with an annual LN2 resupply cost of
around $3,000. Despite these significant expenses, prior to
2011, TPC had not specifically billed for, or attempted to
recover, storage costs through a fee-for-service mechanism.
In 2011 our laboratory implemented such a charge for
investigator-initiated studies (i.e., where specimens are
banked and financed under the protocol of a specific investigator) which is assessed on an annual, per-ampule basis.
From the investigator’s point of view, this means that, based
on the number of post-processing ampules needing storage
(not necessarily the number of tubes or samples originally
submitted), they are assessed charges for all their specimens
occupying liquid nitrogen storage on a given date each year.
The exact date was largely an arbitrary choice, but it was
communicated in advance to the user community. Calculating the correct storage charge (i.e., the one sufficient to
meet cost-recovery objectives) required the TPC to factor
both the cost of maintaining the freezers, and the continuous
resupply of LN2 needed. Our current policy is that no storage
charges are assessed for paraffin blocks, slides, or any other
materials not kept under LN2 vapor. Investigators can elect
to avoid future storage charges by releasing their samples
into the previously described TPC’s general protocol,4 as
Table 3.

long as appropriate regulatory conditions are met, or by requesting the transfer of samples to another bank.

Accessioning and Disbursal
Taking new specimens into the laboratory, and disbursing
them to requesting investigators, are procedures which involve both time and expertise, requiring chain-of-custody
measures, computer entry, and communication efforts. These
processes are reflected as specific charges on TPC’s fee
schedule. The per-specimen accessioning fee is calculated
purely as a labor charge; its disbursal counterpart similarly is
mostly a labor one, but does have a small reagents-andconsumables component to account for materials needed for
the transfer of deliverables to investigators. Neither charge
includes an infrastructure component in the cost calculations.

Laboratory services
Collectively, these services form TPC’s most visible and
recognized core of value, and thus represent items which
investigators usually readily identify with, and show willingness to pay for. Numerous services are offered by the TPC
which are listed specifically on a fee schedule. This schedule
is posted on the laboratory’s website, and shared with investigators (often at the time of initial consultation), and is
updated at least annually. Offered services include plasma,
serum, and Ficoll processing, cytospins, tissue processing

Recommendations for a Successful Fee-for-Service Approach

Recommendation
An outreach program (which could feature seminars,
phone calls, or face-to-face meetings) should be
established which acquaint the potential user base with
the functions and value of the biobank. Also, new fee
schedules should be sent to investigators well in
advance, along with an explanation for the changes.
All external benefits yielded from biobank services (such
as grants or publications that result at least partially
from biobank resources), should be periodically
summarized and communicated.
Quality and accreditation standards (as relevant) should
be maintained and communicated to the user base and
to stakeholders.

Fee-for-service subsidies for certain institutional or other
affiliations can be offered, as a way to incentivize
requests from those sources, or to comply with
institutional or philanthropic support.
Financial support (i.e., defraying certain costs) may be
considered for investigators conducting early ‘‘pilot’’
studies intended to secure subsequent grant
opportunities. Such investigators may be those with the
lease initial financial resources but good long-term
potential.
The biobank may wish to designate a given employee
within its groups, and devote a segment of that
person’s time exclusively to billing and revenue
activities.

Considerations
As with any business, it is important to establish and
maintain good communications with the user base. The
more proactive and value-driven those
communications are, the better. If an academic setting,
the potential value of the bank as a scientific resource to
support grant proposals can be stressed.
Biorepository users, institutional or grant support
sources, and other stakeholders may justifiably demand
an accounting of benefit and quality in return for the
costs incurred, and so impact metrics may be needed.
Besides good customer service, good quality assurance
procedures help ensure support for a fee-for-service
mechanism. The new College of American Pathologists
(CAP) biobank accreditation program, once broadly
implemented, could potentially serve as a quality
standard for resource investments and service-based
fees.7,8
The applicability of this recommendation will of course
depend a great deal on the nature of the biobank, but it
might promote business and enhance revenues longterm.
The applicability of this recommendation will of course
depend a great deal on the situation, but it might
promote business and enhance revenues long-term,
given the potential benefit of investing in early
meritorious studies where financial barriers are initially
present.
This point will depend heavily on the size, complexity,
and resources of the bank. However, it may be a good
idea, given that efficient billing and revenue collection
must underpin any successful business enterprise.

FEE-FOR-SERVICE
and frozen and paraffin section preparation, and DNA and
RNA preparation and analysis. Most laboratory procedures
have labor, reagents-and-consumables, and service contract
cost components built into the calculated fee, which is then
displayed in appropriate delivery units (per mL, per item, or
per cell count). A specialized laboratory service offered by
the TPC is laser capture microscopy (LCM). For this procedure, TPC assesses an hourly charge for use of the LCM
instrument, and charges for needed items (stain sets and
transfer caps).

Pathology review
Pathology review is an essential component of the TPC,
given its focus on neoplastic disease, and the frequent use of
tissues and tissue-based procedures in addressing investigator needs. From an accounting standpoint, this is handled
as a specialized labor charge, with a per-slide pathology review fee (commonly done for quality assurance purposes
when tissue specimens, or molecular products derived from
tissues, are disbursed), or an hourly consultation fee. Such
charges can be waived in some instances where the pathologist receives grant support or manuscript authorship. Besides the obvious accounting benefits, these types of charges
highlight the value that pathologists bring to biorepositories,
and the appropriateness of expecting compensation in exchange for that value.6,7

Recommendations for implementation
Table 3 summarizes our recommendations for implementing a fee-for-service mechanism successfully, once
the right structure has been set using the steps in the Discussion section.
One overarching consideration should be mentioned: The
‘‘inertia’’ factor—loosely defined here as the tendency to resist new ways of doing business, especially when they involve charging for items formerly regarded as ‘‘free’’—has
been an occasional but significant obstacle to adaptation and
change. To alleviate this, the best approach for us has been
persuasive, data-driven, and scientifically motivated advocacy for the new model, made by biorepository staff to its
users. The point to be stressed is that biospecimen science is a
valuable resource that can and should price its services according to a sound financial model. Banks also should periodically evaluate new technologies and services that could
enhance the laboratory’s scientific excellence and provide
new sources of revenue.

Conclusion
Biorepositories operate under an increasingly challenging
financial environment, requiring effective cost-recovery
procedures and other business-savvy approaches designed
to promote biobanking value, and elicit needed financial
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support from customers and stakeholders. The recommendations presented here for implementing a fee-for-service
approach could lead to a more viable business plan for many
biobanks, with greater revenues.
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